{
    "medicine_id": "d69dea5e5a00809bb2dd565e591473c2549b53d8",
    "platform_id": "10802",
    "metadata": {
        "name": "Atazanavir Mylan 150 mg hard capsules Atazanavir Mylan 200 mg hard capsules Atazanavir Mylan 300 mg hard capsules",
        "composition": "150 mg capsules Each capsule contains 150 mg atazanavir as sulphate 200 mg capsules Each capsule contains 200 mg atazanavir as sulphate 300 mg capsules Each capsule contains 300 mg atazanavir as sulphate",
        "clinical_particulars": {
            "therapeutic_indications": "Atazanavir Mylan co administered with low dose ritonavir is indicated for the treatment of HIV 1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products see section 4 2 Based on available virological and clinical data from adult patients no benefit is expected in patients with strains resistant to multiple protease inhibitors 4 PI mutations The choice of Atazanavir Mylan in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient s treatment history see sections 4 4 and 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Atazanavir Mylan is contraindicated in patients with severe hepatic insufficiency see sections 4 2 4 4 and 5 2 Atazanavir Mylan with ritonavir is contraindicated in patients with moderate hepatic insufficiency see sections 4 2 4 4 and 5 2 Co administration with simvastatin or lovastatin see section 4 5 Combination of rifampicin see section 4 5 Combination of the PDE5 inhibitor sildenafil when used for the treatment of pulmonary arterial hypertension PAH only see section 4 5 For co administration of sildenafil for the treatment of erectile dysfunction see sections 4 4 and 4 5 Co administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows e g quetiapine lurasidone alfuzosin astemizole terfenadine cisapride pimozide quinidine bepridil triazolam midazolam administered orally for caution on parenterally administered midazolam see section 4 5 lomitapide and ergot alkaloids particularly ergotamine dihydroergotamine ergonovine methylergonovine see section 4 5 Co administration with grazoprevir containing products including elbasvir grazoprevir fixed dose combination see section 4 5 Co administration with glecaprevir pibrentasvir fixed dose combination see section 4 5 Co administration with products containing St John s wort Hypericum perforatum see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Lactose monohydrate;Crospovidone;Magnesium stearate;Iron oxide red (E172);Titanium dioxide (E171);Patent blue V (E131);Gelatin;Titanium dioxide (E171);Patent blue V (E131);Gelatin;Titanium dioxide (E171);Indigo Carmine (E132);Gelatin;Iron oxide yellow (E172);Titanium dioxide (E171);Patent blue V (E131);Gelatin;Iron oxide yellow (E172);Iron oxide red (E172);Titanium dioxide (E171);Gelatin;Iron oxide red (E172);Titanium dioxide (E171);Patent blue V (E131);Gelatin;Printing ink;Shellac;Propylene glycol;Ammonia solution, concentrated;Iron oxide black (E172);Potassium hydroxide",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2021-06-12"
    }
}